Pfizer Inc. Updates the Public on Clinical Research Programs in Relation to COVID-19

March 31, 2020

Pfizer Worldwide Research Development and Medical, has updated their website’s page dedicated to information regarding COVID-19 and how they are approaching current and planned clinical research programs. The Duchenne Muscular Dystrophy programs are exempt from their three week pause. Phase 1b remains on-going and the start-up activities will continue for the phase 3 study.

To view Pfizer’s website page with information regarding COVID-19, please click here.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open